FibroGen, Inc. (NASDAQ:FGEN – Get Free Report) saw a large increase in short interest during the month of February. As of February 28th, there was short interest totalling 5,300,000 shares, an increase of 79.7% from the February 13th total of 2,950,000 shares. Currently, 5.4% of the shares of the stock are sold short. Based on an average daily volume of 3,330,000 shares, the days-to-cover ratio is currently 1.6 days.
Wall Street Analyst Weigh In
A number of research firms have weighed in on FGEN. HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of FibroGen in a report on Thursday, February 20th. StockNews.com assumed coverage on shares of FibroGen in a report on Friday. They set a “hold” rating for the company.
View Our Latest Stock Report on FGEN
Institutional Inflows and Outflows
FibroGen Stock Up 2.9 %
Shares of FGEN traded up $0.01 during trading on Friday, reaching $0.44. 1,204,677 shares of the company traded hands, compared to its average volume of 2,324,187. The stock has a 50-day simple moving average of $0.51 and a 200-day simple moving average of $0.43. FibroGen has a twelve month low of $0.18 and a twelve month high of $2.80. The stock has a market cap of $44.27 million, a PE ratio of -0.36 and a beta of 0.82.
About FibroGen
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.
Featured Stories
- Five stocks we like better than FibroGen
- 3 Best Fintech Stocks for a Portfolio Boost
- How to Build the Ultimate Everything ETF Portfolio
- Short Selling – The Pros and Cons
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.